Table 3A.

CD4 subsets by study arm—adjusted analysis.

	Visits
	Adjusted means			Adjusted difference in means
Markers	T0 95% CI	T6 95% CI	T12 95% CI	T0 95% CI p-Value	T6 95% CI p-Value	T12 95% CI p-Value	p-Value*
CD4 TM, cells/mm3
RCT arm							0.019
DTG/3TC	45.4 (37.1, 53.8)	60.2 (51.8, 68.5)	56.7 (48.5, 65.0)	0	0	0
B/F/TAF	54.4 (45.6, 63.3)	55.6 (46.8, 64.5)	62.2 (53.2, 71.2)	9.0 (−3.5, 21.5)	−4.6 (−17.1, 8.0)	5.4 (−7.1, 18.0)
				0.161	0.477	0.399
CD4 EMRA, cells/mm3
RCT arm							0.019
DTG/3TC	19.3 (10.8, 27.8)	22.3 (13.8, 30.8)	22.0 (13.6, 30.5)	0	0	0
B/F/TAF	23.8 (14.8, 32.9)	20.2 (11.2, 29.3)	24.8 (15.7, 33.9)	4.6 (−8.3, 17.5)	−2.0 (−14.9, 10.9)	2.7 (−10.2, 15.6)
				0.486	0.758	0.680
CD4 CD57 PD1, cells/mm3
RCT arm							0.159
DTG/3TC	11.3 (7.0, 15.5)	15.7 (11.5, 20.0)	15.8 (11.6, 20.0)	0	0	0
B/F/TAF	15.1 (10.6, 19.6)	15.6 (11.1, 20.1)	19.0 (14.5, 23.6)	3.8 (−2.6, 10.1)	−0.1 (−6.5, 6.2)	3.2 (−3.2, 9.6)
				0.248	0.970	0.323
CD4 subsets (change) by study arm—adjusted analysis.
	Visits
	Adjusted mean changes from T0			Adjusted difference in mean changes from T0
Markers
	T0 95% CI	T6 95% CI	T12 95% CI	T0 95% CI p-Value	T6 95% CI p-Value	T12 95% CI p-Value	p-Value*
CD4 TM, cells/mm3
RCT arm							0.066
DTG/3TC	0.1 (−5.4, 5.7)	11.9 (6.4, 17.5)	13.0 (7.5, 18.4)	0	0	0
B/F/TAF	−0.2 (−6.1, 5.6)	2.3 (−3.6, 8.2)	9.0 (3.1, 15.0)		−9.6 (−17.9, −1.3)	−3.9 (−12.3, 4.4)
					0.025	0.358
CD4 EMRA, cells/mm3
RCT arm							0.285
DTG/3TC	0.1 (−2.5, 2.8)	0.4 (−2.3, 3.0)	3.2 (0.5, 5.8)	0	0	0
B/F/TAF	−0.1 (−2.9, 2.7)	−3.5 (−6.3, −0.7)	0.4 (−2.4, 3.3)		−3.8 (−7.8, 0.1)	−2.7 (−6.7, 1.2)
					0.058	0.179
CD4 CD57 PD1, cells/mm3
RCT arm							0.366
DTG/3TC	−0.1 (−2.5, 2.4)	3.5 (1.0, 5.9)	4.8 (2.3, 7.2)	0	0	0
B/F/TAF	0.1 (−2.5, 2.7)	0.7 (−1.9, 3.3)	3.6 (1.0, 6.3)		−2.8 (−6.4, 0.9)	−1.2 (−4.8, 2.5)
					0.144	0.543

RCT, randomized clinical trial; VL, viral load.

^* F-test type 3 interaction p-value.

^& Adjusted for age, nationality, AIDS, duration of HIV, duration of VL suppression, and CD4 count nadir.